前立腺肥大症治療の世界市場レポート 2025年

前立腺肥大症治療市場規模は、今後数年間で力強い成長が見込まれます。2029年には複合年間成長率（CAGR）5.6％で108億3,000万米ドルに成長します。予測期間の成長は、低侵襲手技の採用の増加、高齢者患者の増加、高度な治療オプションの利用可能性の拡大、患者中心の治療への注目の高まり、併存疾患の有病率の上昇などに起因すると考えられます。この期間に予想される主な動向には、標的治療の開発、デジタルヘルスソリューションの統合、手術オプションの革新、診断のための3D画像の使用、患者中心のケアモデルの進歩などがあります。

低侵襲手術の採用増加は、前立腺肥大症（BPH）治療市場の成長を促進すると予想されます。これらの手術では、回復時間、痛み、合併症のリスクを最小限に抑えるために、専門的な器具を使用して、小さな切開を行うか、切開を行わないです。低侵襲手術への嗜好の高まりは、回復時間の短縮、痛みの軽減、合併症リスクの低下、美容的成果の向上といった利点に起因しています。低侵襲手術によるBPH治療は、合併症が少なく回復が早いため、患者に効果的な症状緩和をもたらします。例えば、米国を拠点とする専門家団体である米国形成外科学会（ASPS）は2023年9月、神経調節剤注射、口唇増大術、非侵襲的スキンタイトニングなどの治療を含む美容的低侵襲手術が2022年に世界で2,367万2,269件行われたと報告しました。その結果、低侵襲手術の採用が増加しており、BPH治療市場の成長に拍車をかけています。

BPH治療市場の主要企業は、患者の転帰を改善し回復時間を短縮するために、革新的なソリューション、特に低侵襲手術に注力しています。これらの手技は切開を最小限または全く伴わないため、従来の手術方法と比較してより早い回復を確保しながら、外傷、痛み、合併症を軽減します。例えば、2022年12月、米国の医療機器メーカーであるテレフレックス・インコーポレイテッドは、前立腺肥大症治療用のウロリフト・システムを発表しました。このシステムは、小型の永久インプラントを使用して肥大した前立腺組織を再配置するもので、組織の切除、切開、加熱を必要とせず、大幅な症状緩和をもたらします。外来治療であるため、迅速な回復が可能で、性機能を維持し、従来のBPH治療薬と比較して優れた症状緩和をもたらし、副作用は通常2～4週間以内に消失します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界前立腺肥大症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の前立腺肥大症治療市場：成長率分析
• 世界の前立腺肥大症治療市場の実績：規模と成長, 2019-2024
• 世界の前立腺肥大症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界前立腺肥大症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の前立腺肥大症治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低侵襲手術
• 侵襲的手術
• 世界の前立腺肥大症治療市場治療クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルファ遮断薬
• 5α還元酵素阻害剤
• ホスホジエステラーゼ5阻害剤
• その他の治療クラス
• 世界の前立腺肥大症治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 在宅ヘルスケア
• 病院と診療所
• 調査と製造
• 世界の前立腺肥大症治療市場低侵襲手術の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経尿道的前立腺切除術（TURP）
• レーザー手術
• 前立腺尿道リフト
• 経尿道的前立腺切開術（TUIP）
• マイクロ波療法
• 世界の前立腺肥大症治療市場侵襲的手術の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 開腹前立腺摘出術
• ロボットによる前立腺切除術

第7章 地域別・国別分析

• 世界の前立腺肥大症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の前立腺肥大症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 前立腺肥大症治療市場：競合情勢
• 前立腺肥大症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co Inc Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline Public Limited Company
• Medtronic Public Limited Company
• Mezzion Pharma Co Ltd
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim
• Boston Scientific Corporation
• Astellas Pharma Inc.
• Olympus Corporation
• Coloplast Group
• Teleflex Incorporated
• Cook Medical Incorporated
• AngioDynamics, Inc.
• HistoSonics Inc
• Urovant Sciences Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 前立腺肥大症治療市場2029：新たな機会を提供する国
• 前立腺肥大症治療市場2029：新たな機会を提供するセグメント
• 前立腺肥大症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Benign prostatic hyperplasia (BPH) treatment encompasses medical, minimally invasive, and surgical approaches aimed at managing symptoms of an enlarged prostate. BPH is a common condition among aging men, often causing urinary problems such as frequent urination, weak stream, and incomplete bladder emptying.

The primary treatment options for BPH include minimally invasive surgery (MIS) and invasive surgery. Minimally invasive surgery (MIS) utilizes small incisions, specialized instruments, and advanced imaging technology to perform procedures with minimal trauma. The therapeutic classes for BPH treatment consist of alpha blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and other therapeutic categories. These treatments serve various end users, including home healthcare, hospitals and clinics, as well as research and manufacturing facilities.

The benign prostatic hyperplasia treatment market research report is one of a series of new reports from The Business Research Company that provides benign prostatic hyperplasia treatment market statistics, including the benign prostatic hyperplasia treatment industry's global market size, regional shares, competitors with a benign prostatic hyperplasia treatment market share, detailed benign prostatic hyperplasia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the benign prostatic hyperplasia treatment industry. This benign prostatic hyperplasia (BPH) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The benign prostatic hyperplasia treatment market size has grown strongly in recent years. It will grow from $8.23 billion in 2024 to $8.71 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be attributed to increasing awareness and screening initiatives, the rising prevalence of BPH, greater healthcare awareness, improvements in healthcare infrastructure, and the growing elderly population.

The benign prostatic hyperplasia treatment market size is expected to see strong growth in the next few years. It will grow to $10.83 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to the rising adoption of minimally invasive procedures, an increasing number of geriatric patients, greater availability of advanced treatment options, a growing focus on patient-centric care, and a rising prevalence of comorbidities. Key trends expected during this period include the development of targeted therapies, integration of digital health solutions, innovations in surgical options, the use of 3D imaging for diagnosis, and advancements in patient-centered care models.

The increasing adoption of minimally invasive surgeries is expected to drive the growth of the benign prostatic hyperplasia (BPH) treatment market. These procedures involve small or no incisions, using specialized instruments to minimize recovery time, pain, and the risk of complications. The growing preference for minimally invasive surgeries is attributed to benefits such as shorter recovery times, reduced pain, lower risk of complications, and improved cosmetic outcomes. BPH treatment through minimally invasive procedures offers patients effective symptom relief with fewer complications and faster recovery. For example, in September 2023, the American Society of Plastic Surgeons (ASPS), a US-based professional association, reported that 23,672,269 cosmetic minimally invasive procedures were performed globally in 2022, including treatments such as neuromodulator injections, lip augmentation, and non-invasive skin tightening. Consequently, the increasing adoption of minimally invasive surgeries is fueling the growth of the BPH treatment market.

Leading companies in the BPH treatment market are focusing on innovative solutions, particularly minimally invasive procedures, to improve patient outcomes and reduce recovery times. These techniques involve minimal or no incisions, reducing trauma, pain, and complications while ensuring faster recovery compared to traditional surgical methods. For instance, in December 2022, Teleflex Incorporated, a US-based medical device company, introduced the UroLift System for BPH treatment. This system uses small permanent implants to reposition enlarged prostate tissue, providing significant symptom relief without requiring tissue removal, cutting, or heating. As an outpatient treatment, it allows for rapid recovery, preserves sexual function, and delivers superior symptom relief compared to conventional BPH medications, with side effects typically resolving within two to four weeks.

In October 2023, Laborie Medical Technologies, Inc., a US-based medical technology company, acquired Urotronic for $600 million. This acquisition aims to expand Laborie's interventional urology portfolio, enhance its technological capabilities, and strengthen its global presence in minimally invasive urological treatments. Urotronic, Inc., a US-based medical device company, specializes in developing and marketing minimally invasive treatments for BPH.

Major players in the benign prostatic hyperplasia treatment market are Pfizer Inc., Merck And Co Inc, AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Public Limited Company, Medtronic Public Limited Company, Mezzion Pharma Co Ltd, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Boston Scientific Corporation, Astellas Pharma Inc., Olympus Corporation, Coloplast Group, Teleflex Incorporated, Cook Medical Incorporated, AngioDynamics, Inc., HistoSonics Inc, Urovant Sciences Ltd, UroGen Pharma Ltd., Urologix Inc, Zenflow Inc, and Butterfly Medical Ltd.

North America was the largest region in the benign prostatic hyperplasia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in benign prostatic hyperplasia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the benign prostatic hyperplasia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The benign prostatic hyperplasia treatment market consists of revenues earned by entities by providing services such as pharmacological treatments, minimally invasive procedures, surgical treatments, diagnostic services, and prostatic stents. The market value includes the value of related goods sold by the service provider or included within the service offering. The benign prostatic hyperplasia treatment market also includes sales of transurethral microwave thermotherapy, prostatic urethral lift, acupuncture, combination therapy, phosphodiesterase-5 inhibitors, and minimally invasive devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Benign Prostatic Hyperplasia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on benign prostatic hyperplasia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for benign prostatic hyperplasia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The benign prostatic hyperplasia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Minimal Invasive Surgery; Invasive Surgery
• 2) By Therapeutic Class: Alpha Blockers; 5-Alpha Reductase Inhibitors; Phosphodiesterase-5 Inhibitors; Other Therapeutic classes
• 3) By End User: Home Healthcare; Hospitals And Clinics; Research And Manufacturing
• Subsegments:
• 1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP); Laser Surgery; Prostatic Urethral Lift; Transurethral Incision of the Prostate (TUIP); Microwave Therapy
• 2) By Invasive Surgery: Open Prostatectomy; Robotic Prostatectomy
• Companies Mentioned: Pfizer Inc.; Merck And Co Inc; AbbVie Inc.; Bayer AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Benign Prostatic Hyperplasia Treatment Market Characteristics

3. Benign Prostatic Hyperplasia Treatment Market Trends And Strategies

4. Benign Prostatic Hyperplasia Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Benign Prostatic Hyperplasia Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Benign Prostatic Hyperplasia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Benign Prostatic Hyperplasia Treatment Market Growth Rate Analysis
• 5.4. Global Benign Prostatic Hyperplasia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Benign Prostatic Hyperplasia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Benign Prostatic Hyperplasia Treatment Total Addressable Market (TAM)

6. Benign Prostatic Hyperplasia Treatment Market Segmentation

• 6.1. Global Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Minimal Invasive Surgery
• Invasive Surgery
• 6.2. Global Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alpha Blockers
• 5-Alpha Reductase Inhibitors
• Phosphodiesterase-5 Inhibitors
• Other Therapeutic classes
• 6.3. Global Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Home Healthcare
• Hospitals And Clinics
• Research And Manufacturing
• 6.4. Global Benign Prostatic Hyperplasia Treatment Market, Sub-Segmentation Of Minimal Invasive Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Transurethral Resection of the Prostate (TURP)
• Laser Surgery
• Prostatic Urethral Lift
• Transurethral Incision of the Prostate (TUIP)
• Microwave Therapy
• 6.5. Global Benign Prostatic Hyperplasia Treatment Market, Sub-Segmentation Of Invasive Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Open Prostatectomy
• Robotic Prostatectomy

7. Benign Prostatic Hyperplasia Treatment Market Regional And Country Analysis

• 7.1. Global Benign Prostatic Hyperplasia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Benign Prostatic Hyperplasia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market

• 8.1. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Benign Prostatic Hyperplasia Treatment Market

• 9.1. China Benign Prostatic Hyperplasia Treatment Market Overview
• 9.2. China Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Benign Prostatic Hyperplasia Treatment Market

• 10.1. India Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Benign Prostatic Hyperplasia Treatment Market

• 11.1. Japan Benign Prostatic Hyperplasia Treatment Market Overview
• 11.2. Japan Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Benign Prostatic Hyperplasia Treatment Market

• 12.1. Australia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Benign Prostatic Hyperplasia Treatment Market

• 13.1. Indonesia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Benign Prostatic Hyperplasia Treatment Market

• 14.1. South Korea Benign Prostatic Hyperplasia Treatment Market Overview
• 14.2. South Korea Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Benign Prostatic Hyperplasia Treatment Market

• 15.1. Western Europe Benign Prostatic Hyperplasia Treatment Market Overview
• 15.2. Western Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Benign Prostatic Hyperplasia Treatment Market

• 16.1. UK Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Benign Prostatic Hyperplasia Treatment Market

• 17.1. Germany Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Benign Prostatic Hyperplasia Treatment Market

• 18.1. France Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Benign Prostatic Hyperplasia Treatment Market

• 19.1. Italy Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Benign Prostatic Hyperplasia Treatment Market

• 20.1. Spain Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Benign Prostatic Hyperplasia Treatment Market

• 21.1. Eastern Europe Benign Prostatic Hyperplasia Treatment Market Overview
• 21.2. Eastern Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Benign Prostatic Hyperplasia Treatment Market

• 22.1. Russia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Benign Prostatic Hyperplasia Treatment Market

• 23.1. North America Benign Prostatic Hyperplasia Treatment Market Overview
• 23.2. North America Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Benign Prostatic Hyperplasia Treatment Market

• 24.1. USA Benign Prostatic Hyperplasia Treatment Market Overview
• 24.2. USA Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Benign Prostatic Hyperplasia Treatment Market

• 25.1. Canada Benign Prostatic Hyperplasia Treatment Market Overview
• 25.2. Canada Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Benign Prostatic Hyperplasia Treatment Market

• 26.1. South America Benign Prostatic Hyperplasia Treatment Market Overview
• 26.2. South America Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Benign Prostatic Hyperplasia Treatment Market

• 27.1. Brazil Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Benign Prostatic Hyperplasia Treatment Market

• 28.1. Middle East Benign Prostatic Hyperplasia Treatment Market Overview
• 28.2. Middle East Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Benign Prostatic Hyperplasia Treatment Market

• 29.1. Africa Benign Prostatic Hyperplasia Treatment Market Overview
• 29.2. Africa Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Benign Prostatic Hyperplasia Treatment Market Competitive Landscape And Company Profiles

• 30.1. Benign Prostatic Hyperplasia Treatment Market Competitive Landscape
• 30.2. Benign Prostatic Hyperplasia Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck And Co Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Benign Prostatic Hyperplasia Treatment Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline Public Limited Company
• 31.2. Medtronic Public Limited Company
• 31.3. Mezzion Pharma Co Ltd
• 31.4. Eli Lilly and Company
• 31.5. Teva Pharmaceutical Industries Ltd.
• 31.6. Boehringer Ingelheim
• 31.7. Boston Scientific Corporation
• 31.8. Astellas Pharma Inc.
• 31.9. Olympus Corporation
• 31.10. Coloplast Group
• 31.11. Teleflex Incorporated
• 31.12. Cook Medical Incorporated
• 31.13. AngioDynamics, Inc.
• 31.14. HistoSonics Inc
• 31.15. Urovant Sciences Ltd

32. Global Benign Prostatic Hyperplasia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Benign Prostatic Hyperplasia Treatment Market

34. Recent Developments In The Benign Prostatic Hyperplasia Treatment Market

35. Benign Prostatic Hyperplasia Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Benign Prostatic Hyperplasia Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Benign Prostatic Hyperplasia Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Benign Prostatic Hyperplasia Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer